Participated · Equity · Mar 2026

Lenoss Medical is a growth-stage biomedical company headquartered in Providence, RI, focused on biological solutions for physiological repair of skeletal defects. Its flagship platform, OsteoPearl®, is an implant and surgical instrument system designed to enable physicians to place natural bone where additional bone is required in spinal vertebral augmentation procedures. The company reported record sales in the fourth quarter and year-over-year surgical procedure growth of nearly 150%, demonstrating accelerating clinical adoption. Management plans to use new capital to expand commercial coverage by hiring regional sales leadership, to increase clinical data generation, and to scale operations and marketing to support further adoption. The company is led by an experienced team of MedTech professionals and counts multiple venture investors and angels among its backers.

Led · Series A · Jan 2024

CRISPR QC has developed what it describes as the world’s first platform to precisely analyze the quality of the CRISPR/Cas9 gene-editing system. The platform standardizes measurements for efficiency and accuracy, enabling pharmaceutical and agriculture companies to quickly screen for the best therapeutics to develop into next-generation personalized medicines. The company is San Diego-based and has opened an office in Scottsdale to tap expertise and talent in Arizona's semiconductor and medical device industries. CRISPR QC closed a $10 million financing led by Xcellerant Ventures. Xcellerant will support the company with strategic decisions as a board member and assist commercialization plans. Management said it engaged with several venture funds before selecting Xcellerant as the lead investor for the Series A. CRISPR QC’s core product is a CRISPR Analytics Platform built on its proprietary CRISPR-Chip, which is uniquely capable of directly measuring CRISPR activity. The platform provides new dimensions of data and analytics intended to accelerate CRISPR product development and to optimize and de-risk gene editing outcomes. Early customers have demonstrated that the platform brings valuable insights throughout the editing process. The company said it will invest its recent seed funding to advance commercial development and further enhance its data analytics capabilities. CRISPR QC positions its platform to empower scientists, researchers, and doctors to achieve safer, more efficacious gene editing outcomes that can support therapies and non-GMO crops. The announcement was released from San Diego.

Participated · Series A · Aug 2023

TruLite Health offers the Truity platform, which focuses on clinical bias and provides multi-level interventions delivered within an integrated EMR workflow. The platform is powered by a curated health equity knowledge base that matches patient clinical and social data to provide personalized recommendations for clinicians and care teams. TruLite says this enables actionable clinical, social, and behavioral interventions at the point of care to close health equity gaps. The company recently entered the commercial market and reports significant early interest that accelerated demand. To support commercial growth, TruLite plans to build out its sales, support, and services staff. The solution is positioned for health systems, payers, and large employers to improve outcomes, provider performance, and lower overall cost of care.

Led · Equity · Oct 2021

Tesis Labs is a targeted genetic sequencing company based in Phoenix, AZ that provides genetic testing and precision medicine services to healthcare providers and physicians. The company offers tools to create personalized care plans for treating chronic diseases such as heart disease, lung disease, and cancer, including across generations. Tesis Labs also supports medical device companies and pharmaceutical firms in bringing new products to market and building a repository of genetic data and research. The company’s proprietary products are currently undergoing clinical validation. Management plans to use the new funds to increase production capability, expand clinical support, and advance several clinical initiatives. Ron King is listed as CEO and Managing Director.